All In Biotech

Drug Trial Radar · NCT03473223

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome

Last checked: Nov 20, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 18,226 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

18,226

Actual

Start

Mar 21, 2018

Primary completion

Feb 16, 2023

Study completion Nov 17, 2023

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Mar 22, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events \[MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke\] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

Conditions

  • Acute Coronary Syndrome

Interventions

  • Apolipoprotein A-I [human] (apoA-I)Biological

    Apolipoprotein A-I \[human\] (apoA-I) purified from human plasma for intravenous administration

  • PlaceboOther

    25% albumin solution diluted to 4.4%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke)Time frame: From the time of randomization through 90 days

Locations

903 sites in 49 countries. Site status is shown where the registry gives one.

  • 8400896 - Advanced Cardiovascular LLC

    Alexander City, Alabama

  • 8400350 - Cardiology, PC

    Birmingham, Alabama

  • 8400337 - Heart Center Research, LLC

    Huntsville, Alabama

  • 8400713 - University of South Alabama College of Medicine

    Mobile, Alabama

  • 8400556 - Mercy Gilbert Medical Center

    Gilbert, Arizona

  • 8400747 - Phoenix V.A. Health Care System

    Phoenix, Arizona

  • 8400772 - Mayo Clinic Arizona

    Phoenix, Arizona

  • 8400996 - Southern Arizona V.A. Healthcare System

    Tucson, Arizona

  • 8400645 - NEA Baptist Clinic

    Jonesboro, Arkansas

  • 8400975 - Central Arkansas Veterans Healthcare System

    Little Rock, Arkansas

  • 8401054 - Central Cardiology Medical Center

    Bakersfield, California

  • 8400379 - John Muir Health and Cardiovascular Institute

    Concord, California

  • 8400931 - Valley Clinical Trials

    Covina, California

  • 8401103 - Orange Coast Memorial Hospital

    Fountain Valley, California

  • 8401166 - Sharp Grossmont Hospital

    La Mesa, California

  • 8401192 - South Orange County Surgical Medical Group

    Laguna Hills, California

  • 8400596 - Long Beach Memorial Medical Center

    Long Beach, California

  • 8400910 - Cardiovascular Innovation and Research Center

    Long Beach, California

  • 8400597 - Los Alamitos Cardiovascular

    Los Alamitos, California

  • 8400693 - University of California Los Angeles

    Los Angeles, California

  • 8400717 - V.A. Greater Los Angeles Healthcare System

    Los Angeles, California

  • 8400888 - Saint Jude Heritage Healthcare

    Mission Viejo, California

  • 8400745 - Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • 8400658 - Valley Clinical Trials, Inc.

    Northridge, California

  • 8400720 - Valley Clinical Trials

    Pasadena, California

  • 8400787 - Riverside Community Hospital

    Riverside, California

  • 8400694 - University of California San Diego Medical Center

    San Diego, California

  • 8400703 - San Diego Cardiac Center

    San Diego, California

  • 8400719 - V.A. San Diego Health Care System

    San Diego, California

  • 8400909 - Ventura Clinical Trials

    Ventura, California

  • 8400891 - John Muir Medical Center Walnu

    Walnut Creek, California

  • 8400893 - Interventional Cardiology Medical Group

    West Hills, California

  • 8400574 - Aurora Denver Cardiology Associates

    Aurora, Colorado

  • 8400684 - UCHealth Memorial Hospital Central - Colorado Springs

    Colorado Springs, Colorado

  • 8400997 - CardioVascular Institute of North Colorado Cardiology Clinic

    Greeley, Colorado

  • 8400670 - Medical Center of the Rockies

    Loveland, Colorado

  • 8400371 - Danbury Hospital

    Danbury, Connecticut

  • 8401134 - Christiana Hospital

    Newark, Delaware

  • 8400779 - MedStar Clinical Research Center

    Washington D.C., District of Columbia

  • 8400688 - George Washington University Medical Center

    Washington D.C., District of Columbia

Showing 40 of 903 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.